Arrowhead Pharmaceuticals Inc. (ARWR) Reports Q3 Loss of $0.96
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $59.53 -0.07%
Financial Fact:
Loss on sale of fixed assets, net: 0
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Loss on sale of fixed assets, net: 0
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.96), versus ($0.68) reported last year. Revenue for the quarter came in at $15.8 million, versus $32.4 million reported last year.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Everus Construction Group, Inc. (ECG) Tops Q3 EPS by 101c ; Offers Guidance
- First Tracks Biotherapeutics, Inc. (TRAX) Misses Q3 EPS by 88c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
